Pharmacologic inhibition of poly(adenosine diphosphate-ribose) polymerase may represent a novel therapeutic approach in chronic heart failure

P. Pacher, L. Liaudet, Jon Mabley, K. Komjati, C. Szabo

Research output: Contribution to journalArticlepeer-review

Abstract

Objectives : We investigated the effects of a novel ultrapotent poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitor, PJ34, on cardiac and endothelial dysfunction in a rat model of chronic heart failure (CHF). Background : Overactivation of the nuclear enzyme PARP importantly contributes to the development of cell dysfunction and tissue injury in various pathophysiologic conditions associated with oxidative stress, including myocardial reperfusion injury, heart transplantation, stroke, shock, and diabetes. Methods : Chronic heart failure was induced in Wistar rats by chronic ligation of the left anterior descending coronary artery. Left ventricular (LV) function and ex vivo vascular contractility and relaxation were measured 10 weeks after the surgery. Nitrotyrosine (NT) formation and PARP activation were detected by immunohistochemistry. Results : Chronic heart failure induced increased NT formation and PARP activation in the myocardium and intramural vasculature, depressed LV performance, and impaired vascular relaxation of aortic rings. PJ34 significantly decreased myocardial PARP activation but not NT formation, and improved both cardiac dysfunction and vascular relaxation. Conclusions : Poly(ADP-ribose) polymerase inhibition represents a novel approach for the experimental treatment of CHF.
Original languageEnglish
Pages (from-to)1006-1016
Number of pages11
JournalJournal of the American College of Cardiology
Volume40
Issue number5
Publication statusPublished - Sept 2002

Fingerprint

Dive into the research topics of 'Pharmacologic inhibition of poly(adenosine diphosphate-ribose) polymerase may represent a novel therapeutic approach in chronic heart failure'. Together they form a unique fingerprint.

Cite this